N/A (device / behavioral)RecruitingNCT07386340
Eversense Gemini flash glucose measurement study
Senseonics multicenter study evaluating the performance and safety of the Eversense Gemini system with flash glucose measurement enhancements against reference glucose and the Eversense 365 CGM.
Primary endpoints
- Sensor and reference glucose agreement across 40-400 mg/dL over 365 days
- Device-related or insertion/removal-procedure-related serious adverse events over 365 days
Results so far
No results posted yet.